Please assess the completion status of the following clinical trial:

Trial Title: A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient~* Male or female age greater than or equal to 18 years at the time of insulin degludec initiation~* Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients~* Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection~* Previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec~* At least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation~* Minimum available data at the time of insulin degludec initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (eGFR) value in the last 12 ±6 months (full data period)~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having signed the Informed Consent in this study~* Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with diabetes (Type: None): Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).

Based on this trial design, predict the completion outcome and termination type (if applicable).